| pubmed-article:16508601 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16508601 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16508601 | lifeskim:mentions | umls-concept:C0020517 | lld:lifeskim |
| pubmed-article:16508601 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:16508601 | lifeskim:mentions | umls-concept:C0010927 | lld:lifeskim |
| pubmed-article:16508601 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:16508601 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:16508601 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16508601 | pubmed:dateCreated | 2006-3-1 | lld:pubmed |
| pubmed-article:16508601 | pubmed:abstractText | Dacarbazine (DTIC) is the first-line chemotherapy for metastatic malignant melanoma without cerebral metastasis. Its clinical and hematological safety is usually good. Hypersensitivity in hepatic failure patients is the most serious side effect described. | lld:pubmed |
| pubmed-article:16508601 | pubmed:language | fre | lld:pubmed |
| pubmed-article:16508601 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16508601 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16508601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16508601 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16508601 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16508601 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:16508601 | pubmed:issn | 0151-9638 | lld:pubmed |
| pubmed-article:16508601 | pubmed:author | pubmed-author:LevyAA | lld:pubmed |
| pubmed-article:16508601 | pubmed:author | pubmed-author:DubertretLL | lld:pubmed |
| pubmed-article:16508601 | pubmed:author | pubmed-author:OllivaudLL | lld:pubmed |
| pubmed-article:16508601 | pubmed:author | pubmed-author:Basset-Seguin... | lld:pubmed |
| pubmed-article:16508601 | pubmed:author | pubmed-author:ArchimbaudAA | lld:pubmed |
| pubmed-article:16508601 | pubmed:author | pubmed-author:KerosSS | lld:pubmed |
| pubmed-article:16508601 | pubmed:author | pubmed-author:GuiteraPP | lld:pubmed |
| pubmed-article:16508601 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16508601 | pubmed:volume | 133 | lld:pubmed |
| pubmed-article:16508601 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16508601 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16508601 | pubmed:pagination | 157-60 | lld:pubmed |
| pubmed-article:16508601 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:meshHeading | pubmed-meshheading:16508601... | lld:pubmed |
| pubmed-article:16508601 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16508601 | pubmed:articleTitle | [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma]. | lld:pubmed |
| pubmed-article:16508601 | pubmed:affiliation | Service de Dermatologie I, Hôpital Saint-Louis, Paris. | lld:pubmed |
| pubmed-article:16508601 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16508601 | pubmed:publicationType | English Abstract | lld:pubmed |
